Crispr Therapeutics Ag (CRSP)
$122.26
0.59 (0.48%)
CRSP Stock Quote Delayed 30 Minutes
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Dogecoin prices and other cryptocurrencies stole the show, and CRISPR stocks sold off.
Louis Navellier's Top 6 Stocks for 2021
He found Apple at $1.49… Intel at $3.60... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 6 Stocks for 2021 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-15.84
EPS
-7.72
Volume (Avg. Vol.)
1,092
Day's Range
121.67 - 121.67
52-Week Range
46.84 - 220.20
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
CRISPR Therapeutics Is a Falling Knife You Don’t Want to Catch
With possibly the worst of the novel coronavirus pandemic over, on the surface CRSP stock seems to be a worthwhile rebound pick. However, the technical outlook suggests otherwise.
Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players.
Cathie Wood Stocks: The Winners and Losers in ARKK ETF Today
Cathie Wood continues to do well in stocks as ARK Innovation ETF (ARKK) gains on Tuesday alongside the company's major holdings.
Why CRSP Stock Is a Less Dicey Risk Asset Today
Crispr Therapeutics offers one of the next big technologies and today shares of CRSP stock afford investors access to growth at a discount.
7 CRISPR Stocks for the Future of Medicine
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.
CRSP Stock: Why CRISPR Therapeutics Shares Are Climbing Today
CRSP stock is rallying today as CRISPR Therapeutics and its gene-editing peers move into the spotlight. Here's what you should know.
Volatility May Continue, But CRISPR Stock Remains a Buy
Even after rebounding in recent weeks, consider now (or any pullback) prime time to enter a long-term position in CRISPR stock.
Crispr Stock Is Volatile, but Worth the Wait as a Buy-and-Hold Biotech Play
This Swiss biotechnology company works on the cutting edge of gene editing and Crispr stock is a play on future treatments.
Crispr Therapeutics News: CRSP Stock Slides 12% on Trial Death
Crispr Therapeutics (CRSP) news for Wednesday includes a patient's death during a recent drug trial dropping CRSP stock down.
CRISPR Therapeutics Stock Is a Strong Buy on the Dip
CRSP stock has pulled back 13% in the last two sessions — on no news. The dip allows investors into a strong long-term story at a lower price.
How to Find the Top Stocks in the Hottest Sectors
Here's how a sector fund can help you find top stocks in sizzling sectors. They’re a great place to start, especially when you want to gain exposure to a specific hypergrowth trend.
Is CRISPR Therapeutics Worth It Without Drugs?
We're still very early in the development of gene editing, and CRISPR Therapeutics is one of the first out of the block. But it's not hte final word.
The Future Could Be Soon for Crispr Therapeutics
Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.
3 Reasons to Go Long Crispr Therapeutics
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
